UNSPSC 51401503: Chlordiazepoxide

This classification denotes a benzodiazepine with the molecular formula C16H14ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6RZ6XEZ3CR, chemically known as 7-chloro-n-methyl-5-phenyl-3h-1,4-benzodiazepin-2-amine 4-oxide but generally known as chlordiazepoxide, which bears US NIH Compound Identifier 2712. European Medicines Agency schedules Chlordiazepoxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06179MIG.

UNSPSC 51401503 Chlordiazepoxide is a Commodity code representing pharmaceutical products purchased by state and local governments; recent state and local solicitations under this code show activity in naloxone and direct-to-manufacturer prescription programs, though the opportunities block reveals minimal direct procurement of chlordiazepoxide itself. State and local purchasers acquiring pharmaceutical products under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Seminole County, Florida represents the county-level buyer type, while the Texas Health and Human Services Commission and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent state-level and multi-state cooperative models. The scope of work encompasses pharmaceutical supply agreements with specified wholesale channels, inventory management through quarterly or regular deliveries, compliance with cGMP and Drug Supply Chain Security Act requirements, and negotiated pricing models that may include fixed pricing, net pricing formats, or WAC-minus structures.

Recent activity spans Florida, Texas, and Minnesota. Seminole County issued IFB 60459723LAS (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with fixed-fee pricing and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 (due April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for direct contracting with self-insured health plans and state agencies, informing future formal solicitations. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement and serving participating jurisdictions including Oregon, issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products, requiring vendors to work through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), with pricing weighted at 75 percent and a two-year contract term beginning July 1, 2026. The code shows modest direct activity; chlordiazepoxide appears underrepresented relative to broader pharmaceutical procurement initiatives focused on naloxone, generic drugs, and multi-state cooperative purchasing frameworks.